Loading clinical trials...

An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants | Clinical Trials | Clareo Health

COMPLETEDPHASE1

An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants

A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BMS-986224 in Participants With Varying Degrees of Renal Function

NCT03634969•Bristol-Myers Squibb

View on ClinicalTrials.gov

Summary

The purpose of this study is to investigate the experimental medication BMS-986224 in participants with varying levels of renal function.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
•BMI ≥18 and ≤ 35kg/m2
•Systolic blood pressure \>100 mmHg

Exclusion Criteria

•Women of childbearing potential or women who are currently pregnant
•Clinically relevant abnormal medical history, abnormal findings on physical examination, vital signs, ECG, or laboratory tests at screening that the investigator judges as likely to interfere with the objectives of the trial or the safety of the volunteer
•Current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect absorption

Locations (3)

Clinical Pharmacology of Miami

Miami, Florida, United States

Orlando Clinical Research Center

Orlando, Florida, United States

Prism Research

Saint Paul, Minnesota, United States

Key Dates

Start Date

August 14, 2018

Primary Completion Date

April 30, 2019

Completion Date

April 30, 2019

Last Updated

February 25, 2020

Enrollment

ACTUAL participants

Conditions

Cardiac FailureMyocardial Failure

Interventions

BMS-986224

DRUG

Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs

NCT06532890

Cardiac FailureGraft Rejection

View study

ACTIVE_NOT_RECRUITINGNA

Physical Exercise and Telephone Follow-up Mediated by Telerehabilitation

NCT05761639

Cardiac Failure

View study

NOT_YET_RECRUITINGPHASE3

ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Failure

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 25, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants

Inclusion Criteria

Exclusion Criteria

Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs

Physical Exercise and Telephone Follow-up Mediated by Telerehabilitation

ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Failure

The Usefulness of Myocardial Work IndeX in ExtraCorporeal Membrane Oxygenation Patients

Levosimendan Administration in Pulmonary Hypertension

A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function